Evidence map›Paper›PMID 31125062›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2019

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon and 28 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 810 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
810citing papers in PubMed, 2 pooled it
62.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

810 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,334 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Efficacy of selpercatinib as a first-line treatment forJournal of comparative effectiveness research · 2026
    Trial
  5. Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  6. Trial
  7. Trial
  8. Review
  9. Management of borderline resectable NSCLC: a narrative review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  10. Article
  11. Granzyme B PET Imaging Reveals LgmnAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

750 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

38 authors at 20 institutions in 9 countries.

J MazieresThoracic Oncology Department, Toulouse University Hospital, Université Paul Sabatier, Toulouse, France. Electronic address: mazieres.j@chu-toulouse.fr.
A DrilonThoracic Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA.
A LusqueBiostatistics Unit, Institut Claudius Regaud, IUCT-O, Toulouse.
L MhannaThoracic Oncology Department, Toulouse University Hospital, Université Paul Sabatier, Toulouse, France.
A B CortotThoracic Oncology Department, Lille University Hospital, Lille University, Lille.
L MezquitaCancer Medicine Department, Gustave Roussy, Villejuif, Paris Sud University Orsay, Paris France.
A A ThaiMedical Oncology Department, Peter MacCallum Cancer Institute, Melbourne, Australia.
C MascauxMultidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, CNRS, INSERM, CRCM, Marseille.
S CouraudRespiratory Diseases and Thoracic Oncology Department, Lyon Sud Hospital, Cancer Institute of Hospices Civils de Lyon, Lyon 1 University.
R VeillonCHU Bordeaux, Respiratory Diseases Department, Bordeaux, France.
M Van den HeuvelFaculty of Medical Science, Radboud University Medical Center, Nijmegen, The Netherlands.
J NealDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, USA.
N PeledSoroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel.
M FrühDepartment of Oncology, Haematology, Cantonal Hospital St Gallen, St Gallen, University of Bern, Switzerland.
T L NgThoracic Oncology Department, University of Colorado Cancer Center, Aurora, USA.
V GounantDepartment of Thoracic Oncology, CIC1425-CLIP2 Paris-Nord, Bichat-Claude Bernard Hospital, APHP, Paris, France.
S PopatRoyal Marsden Hospital, London, UK.
J DieboldCantonal Hospital, Lucerne, Switzerland.
J SabariThoracic Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA.
V W ZhuDepartment of Medicine, Division of Hematology-Oncology, University of California, Irvine School of Medicine, Orange, USA.
S I RothschildDepartment Internal Medicine, University Hospital Basel, Medical Oncology, Basel, Switzerland.
P BironzoDepartment of Oncology, University of Torino, Torino, Italy.
A Martinez-MartiMedical Oncology Department, Vall d'Hebron Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
A Curioni-FontecedroCenter of Hematology and Oncology, University Hospital Zurich, Switzerland.
R RosellCatalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
M Lattuca-TrucPulmonology Department, Grenoble University Hospital, Grenoble, France.
M WieswegDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
B BesseCancer Medicine Department, Gustave Roussy, Villejuif, Paris Sud University Orsay, Paris France.
B SolomonMedical Oncology Department, Peter MacCallum Cancer Institute, Melbourne, Australia.
F BarlesiMultidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, CNRS, INSERM, CRCM, Marseille.
R D SchoutenFaculty of Medical Science, Radboud University Medical Center, Nijmegen, The Netherlands.
H WakeleeDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, USA.
D R CamidgeThoracic Oncology Department, University of Colorado Cancer Center, Aurora, USA.
G ZalcmanDepartment of Thoracic Oncology, CIC1425-CLIP2 Paris-Nord, Bichat-Claude Bernard Hospital, APHP, Paris, France.
S NovelloDepartment of Oncology, University of Torino, Torino, Italy.
S I OuDepartment of Medicine, Division of Hematology-Oncology, University of California, Irvine School of Medicine, Orange, USA.
J MiliaThoracic Oncology Department, Toulouse University Hospital, Université Paul Sabatier, Toulouse, France.
O GautschiUniversity of Bern and Cantonal Hospital, Lucerne, Switzerland.
Université Claude Bernard Lyon 1 · FRUniversité Toulouse III - Paul Sabatier · FRAix-Marseille Université · FRMemorial Sloan Kettering Cancer Center · USPeter MacCallum Cancer Centre · AURadboud University Nijmegen · NLStanford University · USUniversité Paris-Sud · FRUniversity of Bern · CHUniversity of California, Irvine · USUniversity of Colorado Cancer Center · USUniversity of Turin · ITCentre Hospitalier Universitaire de Bordeaux · FRCentre Hospitalier Universitaire de Grenoble · FRInstitut Català d'Oncologia · ESInstitut Claudius Regaud · FRRoyal Marsden Hospital · GBSoroka Medical Center · ILUniversité de Lille · FRUniversity Hospital of Basel · CH

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundAnti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction. PATIENTS AND

methodsWe conducted a retrospective study for patients receiving ICI monotherapy for advanced NSCLC with at least one oncogenic driver alteration. Anonymized data were evaluated for clinicopathologic characteristics and outcomes for ICI therapy: best response (RECIST 1.1), progression-free survival (PFS), and overall survival (OS) from ICI initiation. The primary end point was PFS under ICI. Secondary end points were best response (RECIST 1.1) and OS from ICI initiation.

resultsWe studied 551 patients treated in 24 centers from 10 countries. The molecular alterations involved KRAS (n = 271), EGFR (n = 125), BRAF (n = 43), MET (n = 36), HER2 (n = 29), ALK (n = 23), RET (n = 16), ROS1 (n = 7), and multiple drivers (n = 1). Median age was 60 years, gender ratio was 1 : 1, never/former/current smokers were 28%/51%/21%, respectively, and the majority of tumors were adenocarcinoma. The objective response rate by driver alteration was: KRAS = 26%, BRAF = 24%, ROS1 = 17%, MET = 16%, EGFR = 12%, HER2 = 7%, RET = 6%, and ALK = 0%. In the entire cohort, median PFS was 2.8 months, OS 13.3 months, and the best response rate 19%. In a subgroup analysis, median PFS (in months) was 2.1 for EGFR, 3.2 for KRAS, 2.5 for ALK, 3.1 for BRAF, 2.5 for HER2, 2.1 for RET, and 3.4 for MET. In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2).

conclusions: ICI induced regression in some tumors with actionable driver alterations, but clinical activity was lower compared with the KRAS group and the lack of response in the ALK group was notable. Patients with actionable tumor alterations should receive targeted therapies and chemotherapy before considering immunotherapy as a single agent.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBiomarkers, TumorCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedMutationOncogenesProgrammed Cell Death 1 ReceptorAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, TumorCD274 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 Receptorimmunotherapylung canceroncogenic addiction

Identifiers

PMID31125062
PMCPMC7389252
OpenAlexW2946166987

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.